Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  • Ursula A Matulonis
  • Lydia Walder
  • Trine J Nøttrup
  • Paul Bessette
  • Sven Mahner
  • Marta Gil-Martin
  • Elsa Kalbacher
  • Jonathan A Ledermann
  • Robert M Wenham
  • Kathrine Woie
  • Susie Lau
  • Frederik Marmé
  • Antonio Casado Herraez
  • Anne-Claire Hardy-Bessard
  • Susana Banerjee
  • Gabriel Lindahl
  • Benedict Benigno
  • Joseph Buscema
  • Karin Travers
  • Holly Guy
  • Mansoor R Mirza
View graph of relations

PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer.

PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post-random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs.

RESULTS: In the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons.

CONCLUSION: Patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control.

Original languageEnglish
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume37
Issue number34
Pages (from-to)3183-3191
Number of pages9
ISSN0732-183X
DOIs
Publication statusPublished - 1 Dec 2019

ID: 59076433